Oncoinvent

Third quarter 2025 update

Transforming cancer care through direct alpha therapy

Disclaimer and important information

This presentation, together with its enclosures and appendices (collectively, the "Presentation"), has been prepared by Oncoinvent ASA solely for the purpose of providing existing investors and other stakeholders in the Companies with an update on the company as well as the contemplated merger between the Companies.

THIS PRESENTATION IS FOR INFORMATION AND BACKGROUN PURPOSES ONLY AND DOES TO CONSTITUE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITIES DESCRIBED HEREIN.

By attending a meeting where this Presentation is made, or by reading the Presentation slides, you agree to be bound by the following terms, conditions and limitations, and you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Companies and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Companies and the respective Group, their businesses, shares and other securities. The content of this Presentation is not to be construed as legal, business, investment, or tax advice. Each recipient should consult its own legal, business, investment and tax advisers to obtain legal, business, investment and tax advice. Unless indicated otherwise, the Companies are the source of information included in this Presentation.

The information contained in this Presentation has not been independently verified. No representation or warranty (express or implied) is made as to the accuracy or completeness of any information contained herein, and it should not be relied upon as such. The Companies do not intend or assume any obligation to update the Presentation. Neither the Companies nor any of their subsidiary undertakings or affiliates or any such person's directors, officers, employees, advisors or representatives (collectively the "Representatives") shall have any liability whatsoever arising directly or indirectly from the use of this Presentation.

The Presentation may contain certain forward-looking statements relating to the future business, financial performance and results of the Companies and the respective Groups. Any forward-looking statements contained in this Presentation, including assumptions, opinions and views of the Company or cited from third party sources are solely opinions and forecasts and are subject to risks, uncertainties and other factors that may cause actual events to differ materially from any anticipated development. Neither the Companies nor any of their Representatives provide any assurance that the assumptions underlying such forward-looking statements are free from errors nor do any of them accept any responsibility for the future accuracy of the opinions expressed in this Presentation or the actual occurrence of the forecasted developments. Prior to transacting, potential investors must therefore ensure that they fully understand any applicable risks.

Neither this Presentation, any copy of it nor the information contained herein is being issued nor distributed directly or indirectly to or into Canada, Australia, Hong Kong or Japan, the United States of America or any other jurisdiction in which such distribution would be unlawful. Neither the Companies nor any of their respective Representatives, have taken any action to allow the distribution of this Presentation in any jurisdiction where action would be required for such purposes. The distribution of this Presentation may be restricted by law in certain jurisdictions, and persons into whose possession this Presentation comes should inform themselves about, and observe, any such restriction. Any failure to comply with such restrictions may constitute a violation of the laws of any such jurisdiction. Neither the Companies nor any of their respective Representatives shall have any liability (in negligence or otherwise) for any loss howsoever arising from any use of this Presentation or its contents or otherwise arising in connection with the Presentation.

This Presentation speaks as of 27 August 2025. There may have been changes in matters which affect the Companies or the respective Groups subsequent to the date of this Presentation. Neither the delivery of this Presentation nor any further discussions of the Companies with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of any of the Companies since such date.

This Presentation is subject to Norwegian law, and any dispute arising in respect of this Presentation is subject to the exclusive jurisdiction of Norwegian courts with Oslo district court (Nw: Oslo tingrett) as exclusive venue.

Highlights

Upcoming Milestones

Clinical Update

Recent Highlights

Radspherin®

- **Ovarian cancer:** Reported final results and promising **signal of efficacy** from phase 1 trial
- **Colorectal cancer:** Presented final results from the Phase 1/2a trial at the 15th **PSOGI** International Congress on Peritoneal Surface Malignancies

Corporate

- Completed merger with BerGenBio
- Uplisted to Oslo Stock Exchange from Euronext Growth
- Announced fully underwritten rights issue to be executed in November

Highlights

Upcoming Milestones

Clinical Update

Merger successfully completed, rights issue to be launched 17 November

Details of the merger and the rights issue

Merger successfully completed

- **Merger with BerGenBio successfully completed** 29 October 2025**.**
- Combined company, Oncoinvent ASA, was **uplisted to Oslo Børs and trading under the ticker code "ONCIN" from 30 October 2025.**
- **No action required by any shareholder.**
  - Oncoinvent's shareholders have received consideration shares 3 November (record date 31 October 2025).
  - No changes to BerGenBio's shareholders other than change of name and ticker from 30 October.

Fully underwritten rights issue of NOK 130 mill.

11 Nov.	• **Price date** – based on Volume Weighted Average Price previous 9 trading date
13 Nov.	• **Record date** – existing shareholders will receive tradable subscription rights under ticker **ONCIT**
17-25 Nov.	• **Subscription rights** will be **tradable** from 17 November at 09:00 until 25 November 2025 at 16:30
17-01 Nov./Dec.	• **Subscription period** 17 November at 09:00 and expire on 1 December at 16:30
02 Dec.	• **Allocation of shares** with an expected delivery on 9 December
4 Dec.	• **Payment date**

All dates are on or about

Cash and runway

Cash Oncoinvent per end 3Q	As of the 30. September 2025 Oncoinvent had a total of **NOK 45 mill.** in cash and cash equivalents
Estimated cash from BerGenBio and rights issue	As at the date of the Prospectus, the Company holds approximately **NOK 45 mill.** in cash and cash equivalents Fully underwritten rights issue in November **NOK 130 mill**
Runway	Into 2027

Ongoing clinical development



Highlights

Upcoming Milestones

Clinical update

Ongoing clinical development



Ongoing clinical development



Radspherin® - phase 1 study in ovarian cancer

RAD-18-001: in patients after secondary debulking surgery of platinum-sensitive recurrent ovarian cancer

- single-arm open label study
- 3 + 3 dose-escalation (1, 2, 4, 7 MBq)
- 24 months follow-up

4 clinical sites:

- Oslo, Norway (PI: Yun Wang)
- Leuven, Belgium (PI: Els van Nieuwenhuysen)
- Madrid, Spain (PI: Luis Chiva)
- Pamplona, Spain (PI: Luis Chiva)



Total number of patients recommended dose 7MBq, **n=10**

Radspherin® - phase 1 study in ovarian cancer - safety

	Dose 1MBq (n=3)	Dose 2 MBq (n=3)	Dose 4 MBq (n=4)	Dose 7 MBq (n=11)	Total (n=21)
Number of adverse events	18	22	24	42	106
Patients with at least one adverse event	3 (100 %)	3 (100 %)	4 (100 %)	10 (100 %)	21 (100 %)
Number of adverse events leading to death	0	0	0	0	0
Numbers of serious adverse events	0	3	2	1	6
Number of dose limiting toxicity	0	0	0	0	0
Number of study drug related adverse events	0	0	0	3	3
Number of study drug related adverse events, grade 3 or higher	0	0	0	0	0

Adverse events, safety set (n=21)

- The most frequently reported adverse events were nausea, abdominal pain, constipation, vomiting, urinary tract infections
- No increase of rates of events with increasing dose levels
- 6 serious adverse events
  - Non-related: transient ileus (3), compression fracture (1)
  - Related: procedural complication (1)
- Study drug related adverse events (all grade 1 or 2)
  - Procedural complication
  - Abdominal pain
  - Abdominal discomfort

Radspherin® - phase 1 study in ovarian cancer - efficacy

24 months data from 10 patients receiving 7 MBq dose vs historical recurrence rates

"These final results are **truly encouraging**, suggesting that Radspherin® could help **delay disease progression and offer patients hope for longer, healthier lives**. It is particularly promising to see that the new recurrences were limited to lymph nodes, which are typically associated with **longer survival** compared to peritoneal relapses.

Dr Luis Chiva, Principal Investigator and Director of Department of Obstetrics and Gynecology Clinica Universidad de Navarra

Recurrence rates RAD-18-001





10%

Peritoneal recurrence rate

One patient with recurrence

30%

Overall recurrence rate

Additionally, two extra-abdominal lymph node recurrences

Radspherin® - phase 1 study in ovarian cancer - efficacy

24 months data from 10 patients receiving 7 MBq dose vs historical recurrence rates

"These final results are **truly encouraging**, suggesting that Radspherin® could help **delay disease progression and offer patients hope for longer, healthier lives**. It is particularly promising to see that the new recurrences were limited to lymph nodes, which are typically associated with **longer survival** compared to peritoneal relapses.

Dr Luis Chiva, Principal Investigator and Director of Department of Obstetrics and Gynecology Clinica Universidad de Navarra

Recurrence rates RAD-18-001



10%

Peritoneal recurrence rate

One patient with recurrence



30%

Overall recurrence rate

Additionally, two extra-abdominal lymph node recurrences

Recurrence rates historical controls



~55-60%

Overall recurrence rate*

*Peritoneal recurrence rates or distribution of recurrences not available in historical controls

Coleman et al. N Engl J Med. 2019 Nov 14;381(20):1929-1939
Harter et al. N Engl J Med. 2021 Dec 2;385(23):2123-2131
Shi et al. Lancet Oncol. 2021 Apr;22(4):439-449

Ongoing clinical development



Phase 2 study in ovarian cancer – frontline treatment setting

Patients
- with peritoneal metastases
- after neoadjuvant chemotherapy
- eligible for complete resection (R0)
- with HRD negative ovarian cancer



Assessment every 3 months up to 24 months, including CT/MRI

Primary endpoint: progression-free survival

Long-term follow- up for up to 5 years according to standard of care

6 study sites actively enrolling:
NO, BE, ES (2), UK, US

PFS: Progression Free Survival
pPFS: peritoneal Progression Free Survival
OS: Overall Survival

AESI: Adverse Event of Specialized interest
TFST: time to first subsequent anticancer therapy or death
TSST: time to second subsequent anticancer therapy or death

HRD: Homologous Recombination Deficiency
IDS: Interval Debulking Surgery

Patient recruitment update end Q3

- All six hospitals are **actively recruiting** patients and patient recruitment is **on track**
- Recruitment in July and August was seasonally limited.
- A total of 22 (of 108) patients per intention to treat or 19 (out of 96 patients) per protocol have been recruited by end September vs 14 (on both counts) end June



- Number of **hospitals will increase** in November and December, which will speed up recruitment rate
- Selected **changes to protocol** in 2H25 will strengthen recruitment further

Ongoing clinical development



Presentation of Phase 1/2a study results in colorectal cancer

The 15th PSOGI International Congress on Peritoneal Surface Malignancies
Barcelona 2025
October 29th •31st, 2025



Peritoneal recurrence rate in 36 patients receiving 7 MBq dose vs historical control

Radspherin®	Historical control
	
28%	~50%
Peritoneal recurrence rate	Peritoneal recurrence rate

Quenet et al. Lancet Oncol. 2021 Feb;22(2):256-266

Near-term significant milestone

Phase 2
ovarian cancer

- Interim data
- Following complete recruitment
- **2H26**

Phase 1
ovarian cancer

- Final 24 months data
- 10 patients 7 MBq
- October 2025

Phase 1/2a
colorectal cancer

- Final 18 months data
- 36 patients 7 MBq
- June 2025

Financial Calendar

today	Quarterly update Q3-25
26 February	Half-year report H2-25
30 April	Quarterly update Q1-26
20 May	Annual General Meeting
27 August	Half-year report H1-26
28 October	Company update Q3-26

Questions